7-(furan-2-yl)-6-(pyrimidin-4-yl)pyrido[2,3-d]pyrimidine-2,4-(1H,3H)-dione | 1221900-03-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 7-(furan-2-yl)-6-(pyrimidin-4-yl)pyrido[2,3-d]pyrimidine-2,4-(1H,3H)-dione
• 英文别名: 7-(furan-2-yl)-6-(pyrimidin-4-yl)pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione；7-(furan-2-yl)-6-pyrimidin-4-yl-1H-pyrido[2,3-d]pyrimidine-2,4-dione
• CAS: 1221900-03-3
• 化学式: C₁₅H₉N₅O₃
• 分子量: 307.268
• InChiKey: VYTAHRSDFGGCON-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  23
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  110
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  2-amino-6-(2-furyl)-5-pyrimidin-4-ylnicotinic acid 、 尿素 以58%的产率得到7-(furan-2-yl)-6-(pyrimidin-4-yl)pyrido[2,3-d]pyrimidine-2,4-(1H,3H)-dione
  参考文献：
  名称：

  Discovery of potent and selective bicyclic A2B adenosine receptor antagonists via bioisosteric amide replacement

  摘要：

  Several new potent and selective A(2B) adenosine receptor antagonists have been prepared in which the aryl-amide moiety of the lead series, exemplified by 1a, has been replaced by bioisosteric bicyclic moieties. Although the majority of compounds had generally improved microsomal stability as compared to 1a, this was not translated into overall improvements in the pharmacokinetic profiles of a representative set of compounds. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.01.077

文献信息

• Discovery of potent and selective bicyclic A2B adenosine receptor antagonists via bioisosteric amide replacement
  作者：Paul Eastwood、Jacob Gonzalez、Sergio Paredes、Silvia Fonquerna、Arantxa Cardús、Juan Antonio Alonso、Arsenio Nueda、Teresa Domenech、Raquel F. Reinoso、Bernat Vidal

  DOI：10.1016/j.bmcl.2010.01.077

  日期：2010.3

  Several new potent and selective A(2B) adenosine receptor antagonists have been prepared in which the aryl-amide moiety of the lead series, exemplified by 1a, has been replaced by bioisosteric bicyclic moieties. Although the majority of compounds had generally improved microsomal stability as compared to 1a, this was not translated into overall improvements in the pharmacokinetic profiles of a representative set of compounds. (C) 2010 Elsevier Ltd. All rights reserved.